Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Identification of genomic determinants contributing to cytokine release in immunotherapies and human diseases

Fig. 3

PFKFB4 expression and glycolytic pathway activity is also enhanced in some human diseases associated with cytokine release syndrome. PFKFB4 gene expression profile in COVID-19 patients vs healthy donor (A), COVID-19 patients with severe symptoms vs moderate symptoms (B), healthy donors vs asymptomatic vs recovered vs re-infected COVID-19 patients (C). Glycolytic activity score in COVID-19 patients vs healthy donors (D), COVID-19 patients with severe symptoms vs moderate symptoms (E), healthy donors vs asymptomatic vs recovered vs re-infection COVID-19 patients (F). PFKFB4 gene expression in people infected with influenza based on early and late stage infection (G–I). PFKFB4 gene expression in different stages of SLE (J) and SJIA (K). HD healthy donor, As asymptomatic, SLE systemic lupus erythematosus, SJIA systemic juvenile idiopathic arthritis

Back to article page